Your browser doesn't support javascript.
loading
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Konecny, Gottfried E; Pegram, Mark D; Venkatesan, Natarajan; Finn, Richard; Yang, Guorong; Rahmeh, Martina; Untch, Michael; Rusnak, David W; Spehar, Glenn; Mullin, Robert J; Keith, Barry R; Gilmer, Tona M; Berger, Mark; Podratz, Karl C; Slamon, Dennis J.
Affiliation
  • Konecny GE; Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 12-145 Factor Building, 10945 Le Conte Avenue, Los Angeles, CA 90095-1678, USA. gkonecny@ucla.edu
Cancer Res ; 66(3): 1630-9, 2006 Feb 01.
Article in En | MEDLINE | ID: mdl-16452222
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Cancer Res Year: 2006 Document type: Article Affiliation country: United States Country of publication: United States
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Cancer Res Year: 2006 Document type: Article Affiliation country: United States Country of publication: United States